Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,520.36
(
0.02%
)
US TECH 100
29,112.68
(
-0.34%
)
Dow Jones
50,644.28
(
0.36%
)
Brent Oil
95.24
(
3.03%
)
Bitcoin
72,855.04
(
-2.71%
)
News Focus
News Focus
Post# of 257648
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

kris_kade

Send PM Follow Ignore
Followers 22
Posts 1671
Boards Moderated 0
Alias Born 12/12/2006

kris_kade

Re: researcher59 post# 156822

Monday, 02/11/2013 10:28:07 PM

Monday, February 11, 2013 10:28:07 PM

Post# of 257648
Agree..the institutions paid $25+ and they were oversubscribed ! SRPT is unlikely to go any lower than low 20's. A likely scenario is FDA may ask SRPT to do a controlled but short trial (aka expanded PI) in line with their new paradigm shift of supporting pathways for innovative drugs. Eteplirsen definitely qualifies in that regard.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today